-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Benzinga·06/15/2026 14:09:15
Listen to the news
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.